Pacira BioSciences (PCRX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Pacira BioSciences (PCRX) do?
Pacira BioSciences Inc (PCRX) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Manufactures and commercializes non-opioid injectable medications and handheld cryoanalgesia devices for postsurgical pain control. Formulates extended-release non-opioid pain therapies using proprietary multivesicular liposome delivery technology for. It is worth $1.46B on the market and sold $742.46M over the last year.
- Market cap
- $1.46B
- P/E ratio
- 39.5×
- Annual sales
- $742.46M
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 12, 2026
Brands and businesses behind PCRX
- EXPAREL: Injectable suspension that delivers long-lasting postsurgical local analgesia to reduce patient opioid consumption.
- ZILRETTA: Extended-release injectable suspension formulated with microspheres to manage osteoarthritis knee pain.
- iovera: Handheld cryoneurolysis device that freezes peripheral nerves to provide immediate and prolonged drug-free pain relief.
PCRX’s flags, in plain English
Each flag is a number from Pacira BioSciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.
Stupid Cash
Can pay this year's bills 4.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 71.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Growth vs Price
The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.
Priced for Perfection
Priced at 39.5 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about PCRX
How big is Pacira BioSciences?
Pacira BioSciences’ market cap is $1.46B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $742.46M: what customers paid the company over the last year, before any costs.
What is PCRX’s P/E ratio?
PCRX’s P/E ratio is 39.5×. Investors pay about 39.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with PCRX?
The business depends on Exparel for the vast majority of its revenue, leaving it exposed to generic competition and patent litigation. That is one risk on Pacira BioSciences’ card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Pacira BioSciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PCRX’s filings on SEC.gov. The Margin Monkey is research, not advice.
